Market Overview

UPDATE: Barclays Raises PT to $57 on CVS Caremark Following Meeting with Management

Share:
Related CVS
Winners And Losers If The Walgreens-Rite Aid Merger Is Blocked
The Difference Between Mylan's EpiPen And Generic Offerings
Implications Of The Latest Smash In Bristol-Myers Squibb Stock (Seeking Alpha)

Barclays reiterated its Overweight rating on CVS Caremark (NYSE: CVS) and raised its price target from $54 to $57.

Barclays noted, "At CVS Caremark's 2012 analyst meeting, management showed investors how the company's business model gives it meaningful competitive advantages as the US healthcare industry is transformed. [P]erhaps most significant, is the change in rationale for payments to healthcare providers, especially doctors and hospitals, as the nation moves from fee-for-service to outcomes-based payment. We see many approaches to pay-for-performance, but encouraging patients to remain adherent to their medications is crucial to all of them."

CVS Caremark closed at $49.24 on Friday.

Latest Ratings for CVS

DateFirmActionFromTo
Dec 2016JefferiesAssumesBuyHold
Oct 2016UBSInitiates Coverage onBuy
Oct 2016Bank of AmericaMaintainsBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!